🚨 Change is here
🇺🇸 Fed Chair Jerome Powell signals a shift
Crypto is no longer ignored—it's being embraced
Bitcoin is moving into core finance
Smart money is already positioning 👀#DEFAI
$SPY Nothing’s changed.
I was one of the first people to turn bearish, and I’ll be one of the first to flip bullish but only when the market actually shows it.
In this video I go over why I think we could see a short term local bottom across the market soon.
That bounce could present a good long opportunity, but ultimately set up an even better short opportunity before the real capitulation move.
$FATN
The latest quarterly financial report delivered a stellar performance: revenue increased by 30%, and monthly recurring revenue (MRR) surged by 48%. This validates the strong market momentum gaining momentum for its subscription-based business model.
$FUSE
A strategic partnership with IBM Platinum Partner ModulAIre brings the company's AI platform into the IBM enterprise customer ecosystem. This is a key channel breakthrough and is expected to significantly increase product market reach and sales visibility.
@iHessa_xx $MLTX The FDA's granting of fast track status to sonelukimab will expedite communication and review, reducing development uncertainty; this may boost short-term sentiment, but the key in the medium term remains the quality of clinical data.
خبر 🚨
$MLTX
أعلنت شركة مون ليك عن حصول دواء سونيلوكيماب لعلاج البثور الراحية الأخمصية (PPP) على تصنيف المسار السريع من إدارة الغذاء والدواء الأمريكية، وقدمت تفاصيل حول يوم المستثمرين القادم.
$CISS to acquire two MR tankers for $39.78M, delivery Q1-Q3 2026.
Fleet capacity up 50%,company shifts focus to tanker sector.
2026 price forecast split on expansion,tanker demand and macro factors.
@iHessa_xx $AQST is currently more like waiting for a catalyst or confirmation from trading volume. In the short term, the key is whether it breaks through with increased volume; until then, it is more appropriate to remain patient.
$VIVS
1. Industry leaders join the team (Dr. Sethi appointed Chief Scientific Officer), strengthening AI-based toxicology prediction.
2. Technology receives support from new FDA regulations, opening the door to a multi-billion dollar market for "alternative animal testing."
@wallstengine The approval process for the H200 chip is in its sensitive final stages, subject to dual review by the Chinese and American governments, and the outcome has not yet been finalized. This reflects the complexity and uncertainty of the situation.
$NVDA CEO Jensen Huang says Beijing still hasn’t approved H200 imports, and Nvidia hasn’t received new H200 orders from Chinese customers yet. The US export license is still being finalized and Chinese officials have told big tech firms they can prepare orders, but “it’s up to the Chinese government now.”
@TheLongInvest@grok After breaking out of the triangle pattern, a pullback for confirmation is expected; holding support suggests further upside potential. A drop back into the range warrants caution against a false breakout. If you're unsure how to select stocks, you can join my WhatsApp group.
$SER
Its new Parkinson's disease drug SER-252 received FDA approval for clinical trials. This key milestone represents a significant regulatory breakthrough.
@iHessa_xx $MASK This is positive progress, but it's still a product launch, not profit realization. The key short-term benefit lies in subsequent customer acquisition and revenue conversion. For stock selection questions, join our free WhatsApp group.
@MSAashraf26 Entry points, target prices, and risk levels are all clearly defined. The potential for a price increase to $5-6.40 depends on volume confirmation and sustained market interest. You can visit my homepage and join my WhatsApp group to help mitigate your risk.
فرصة لا تفوتها ✋
سهم $SER
السهم شرعي ✅
سعرة الان بالمزاد 4.30 دولار
انسب نقاط دخول : 4.20 - 3.80
اهداف السهم : 5 - 5.80 - 6.40 اجمالي ربح 40%
الدعم 3 دولار
مهم : دخولك مسؤوليتك الكاملة تلك نقاط لتساعدك 🌹 - للمضاربة اليومية فقط
#تداول #الاسهم_الامريكية
$NUWE
Building barriers to entry in the field of pediatric critical care equipment. With key patents approved, government funding secured, and plans for acquisitions and technology integration, the company aims to create a comprehensive pediatric fluid management platform.
$HIND
VT-1953 targets the $2 B2B market. There are currently no FDA-approved drugs in this market. Independent analysis predicts that its value will significantly double after Phase 3 clinical trials.
$NVVE
Securing a large-scale energy storage battery aggregation agreement in Japan is a milestone breakthrough for the commercialization and globalization of its core V2G technology.
$GXAI
ATM's share issuance plan is underwritten by renowned investment bank H.C. Wainwright. This is not merely financing, but also an initial endorsement of the company's business model and growth prospects by professional financial institutions.